Baseline laboratory test abnormalities are common in early arthritis but rarely contraindicate methotrexate: study of three cohorts (ESPOIR, VErA, and Brittany).

[1]  Eugene Yang,et al.  A clinician’s perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation – full speed ahead or proceed with caution? , 2014, Vascular health and risk management.

[2]  M. Dougados,et al.  Is routine viral screening useful in patients with recent‐onset polyarthritis of a duration of at least 6 weeks? Results from a nationwide longitudinal prospective cohort study , 2011, Arthritis care & research.

[3]  J. Ménard,et al.  Serum IgA rheumatoid factor and pyridinoline in very early arthritis as predictors of erosion(s) at two years: A simple model of prediction from a conservatively treated community‐based inception cohort , 2010, Arthritis care & research.

[4]  T. Pincus,et al.  Underestimation of the efficacy, effectiveness, tolerability, and safety of weekly low-dose methotrexate in information presented to physicians and patients. , 2010, Clinical and experimental rheumatology.

[5]  Laure Gossec,et al.  Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis , 2010, Annals of the rheumatic diseases.

[6]  John Wong,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs , 2010, Annals of the rheumatic diseases.

[7]  D. M. van der Heijde,et al.  Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature. , 2009, Clinical and experimental rheumatology.

[8]  M. Dougados,et al.  Is Screening for Hepatitis B and Hepatitis C Useful in Patients with Recent-Onset Polyarthritis? The ESPOIR Cohort Study , 2009, The Journal of Rheumatology.

[9]  Jeffrey R Curtis,et al.  American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. , 2008, Arthritis and rheumatism.

[10]  P Bourgeois,et al.  Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study. , 2007, Rheumatology.

[11]  M. Dougados,et al.  The ESPOIR cohort: a ten-year follow-up of early arthritis in France: methodology and baseline characteristics of the 813 included patients. , 2007, Joint, bone, spine : revue du rhumatisme.

[12]  C. Allaart,et al.  Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. , 2007, Arthritis and rheumatism.

[13]  F. Wolfe,et al.  Anemia and renal function in patients with rheumatoid arthritis. , 2006, The Journal of rheumatology.

[14]  M. Dougados,et al.  Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. , 2006, Joint, bone, spine : revue du rhumatisme.

[15]  S. van Hooland,et al.  METHOTREXATE SHOULD NOT BE USED FOR PATIENTS WITH END-STAGE KIDNEY DISEASE , 2006, Acta clinica Belgica.

[16]  F. Guillemin,et al.  Laboratory and imaging studies used by French rheumatologists to evaluate patients with early arthritis. , 2006, The Journal of rheumatology.

[17]  C. Caramella,et al.  Is low-dose methotrexate nephrotoxic? Case report and review of the literature. , 2005, Clinical nephrology.

[18]  C. Michet,et al.  Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis. , 2004, The Journal of rheumatology.

[19]  T. Pincus,et al.  Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities , 2004, Annals of the rheumatic diseases.

[20]  H. Anders,et al.  Assessment of Renal Function in Rheumatoid Arthritis: Validity of a New Prediction Method , 2002, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[21]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[22]  J. Mary,et al.  Ability of the American College of Rheumatology 1987 criteria to predict rheumatoid arthritis in patients with early arthritis and classification of these patients two years later. , 2001, Arthritis and rheumatism.

[23]  G. Alarcón.  Methotrexate use in rheumatoid arthritis. A Clinician's perspective. , 2000, Immunopharmacology.

[24]  C. Bologna,et al.  Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients , 1998, Annals of the rheumatic diseases.

[25]  J. O'dell,et al.  Methotrexate use in rheumatoid arthritis. , 1997, Rheumatic diseases clinics of North America.

[26]  M Macaluso,et al.  Risk Factors for Methotrexate-Induced Lung Injury in Patients with Rheumatoid Arthritis: A Multicenter, Case-Control Study , 1997, Annals of Internal Medicine.

[27]  B. Bannwarth,et al.  [Methotrexate and non-steroidal anti-inflammatory agent combination in rheumatoid arthritis]. , 1997, Therapie.

[28]  Randall G. Lee,et al.  Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. , 1993, Arthritis and rheumatism.

[29]  A. Baer,et al.  The pathogenesis of anemia in rheumatoid arthritis: a clinical and laboratory analysis. , 1990, Seminars in arthritis and rheumatism.

[30]  M. Guttadauria,et al.  Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. , 1985, Arthritis and rheumatism.

[31]  M. Weinblatt,et al.  Efficacy of low-dose methotrexate in rheumatoid arthritis. , 1985, The New England journal of medicine.

[32]  T. Taylor,et al.  Low dose oral methotrexate in rheumatoid arthritis: an uncontrolled trial and review of the literature. , 1983, Seminars in arthritis and rheumatism.

[33]  S SmolenJosef,et al.  EULAR (欧州リウマチ学会) 合成および疾患修飾性抗リウマチ生物学的製剤による関節リウマチ管理に関する推奨ガイドライン | 文献情報 | J-GLOBAL 科学技術総合リンクセンター , 2010 .

[34]  P. Hannonen,et al.  Renal safety of initial combination versus single DMARD therapy in patients with early rheumatoid arthritis: an 11-year experience from the FIN-RACo Trial. , 2010, Clinical and experimental rheumatology.

[35]  Kdoqi Disclaimer.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[36]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .

[37]  C. Bombardier,et al.  Published Online First , 2007 .